ZIVO - Zivo Bioscience, Inc. Stock Price, Fair Value and News

8.00USD0.00 (0.00%)Delayed

Market Summary

USD8.000.00

Delayed

0.00%

ZIVO Stock Price

View Fullscreen

ZIVO RSI Chart

ZIVO Valuation

Market Cap

22.2M

Price/Earnings (Trailing)

-2.86

Price/Sales (Trailing)

803.66

Price/Free Cashflow

-3.83

ZIVO Price/Sales (Trailing)

ZIVO Profitability

Return on Equity

352.57%

Return on Assets

-1.4K%

Free Cashflow Yield

-26.1%

ZIVO Fundamentals

ZIVO Revenue

Revenue (TTM)

27.6K

Rev. Growth (Yr)

-96.66%

ZIVO Earnings

Earnings (TTM)

-7.8M

Earnings Growth (Yr)

27.73%

Earnings Growth (Qtr)

-4.58%

Breaking Down ZIVO Revenue

Last 30 days

-9.3%

Last 90 days

20.3%

Trailing 12 Months

167.6%

How does ZIVO drawdown profile look like?

ZIVO Financial Health

Current Ratio

0.15

Debt/Equity

-6.37

Debt/Cashflow

-0.41

ZIVO Investor Care

Shares Dilution (1Y)

76.93%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	27.6K
2022	0	0	0	0
2021	0	0	0	0
2020	0	0	0	0
2019	1.8M	2.3M	2.4M	2.0M
2018	2.0M	2.1M	1.4M	2.0M
2017	2.0M	1.0M	1.9M	1.8M
2016	1.3M	1.5M	1.7M	1.9M
2015	0	0	0	1.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Zivo Bioscience, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 02, 2024	cornell alison a	bought	49,999	1.2	41,666	-
Dec 29, 2023	maggiore christopher d.	bought	205,000	1.3	157,692	-
Dec 13, 2023	maggiore christopher d.	bought	45,000	1.00	45,000	-
Dec 19, 2022	masterson nola e	bought	792	2.64	300	-
Dec 19, 2022	payne john bernard	bought	142	2.5	57.00	president and ceo
Dec 13, 2022	cornell alison a	bought	36,000	3.00	12,000	-
Sep 14, 2022	maggiore christopher d.	bought	25,447	3.53438	7,200	-
Feb 11, 2022	maggiore christopher d.	bought	173,952	3.8686	44,965	-
Feb 10, 2022	maggiore christopher d.	bought	65,451	3.635	18,006	-

Which funds bought or sold ZIVO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 22, 2024	PNC Financial Services Group, Inc.	sold off	-100	-818	-	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-170,126	-	-%
Feb 14, 2024	BARTLETT & CO. WEALTH MANAGEMENT LLC	sold off	-100	-1,300	-	-%
Feb 14, 2024	BARTLETT & CO. WEALTH MANAGEMENT LLC	new	-	216	216	-%
Feb 14, 2024	CVI Holdings, LLC	sold off	-100	-7,216	-	-%
Feb 14, 2024	Royal Bank of Canada	sold off	-100	-	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	sold off	-100	-7,974	-	-%
Feb 13, 2024	ARMISTICE CAPITAL, LLC	sold off	-100	-1,042,430	-	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-6,956	-	-%
Feb 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	sold off	-100	-360,193	-	-%

Are Funds Buying or Selling ZIVO?

Are funds buying ZIVO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ZIVO

No. of Funds

Unveiling Zivo Bioscience, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 09, 2024	strome mezzanine fund, lp	2.1%	57,506	SC 13D/A
Jan 22, 2024	maggiore christopher d.	12.8%	355,158	SC 13D
Oct 30, 2023	strome mezzanine fund, lp	3.3%	345,036	SC 13D/A
Feb 14, 2023	maggiore christopher d.	10.2%	979,744	SC 13D/A

Recent SEC filings of Zivo Bioscience, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 09, 2024	SC 13D/A	13D - Major Acquisition
Mar 15, 2024	10-K	Annual Report
Mar 14, 2024	SCHEDULE 13D/A	SCHEDULE 13D/A
Feb 15, 2024	8-K	Current Report
Feb 15, 2024	25-NSE	25-NSE
Jan 22, 2024	SC 13D	13D - Major Acquisition
Jan 17, 2024	8-K	Current Report

Peers (Alternatives to Zivo Bioscience, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.9B	6.8B	-0.89%	-25.81%	-8.47	5.83	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.46%	-30.31%	-41.72	10.05	76.23%	61.08%
BMRN	16.9B	2.4B	5.17%	-8.18%	100.76	6.98	15.42%	18.43%
INCY	11.7B	3.7B	-8.90%	-30.41%	19.5	3.15	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-13.99%	-44.77%	-10.87	14.48	425.83%	18.94%
BBIO	4.4B	-	-15.28%	57.81%	-6.75	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-11.84%	-2.48%	-14.08	12.45	440.80%	-27.84%
ARWR	3.0B	240.7M	-11.98%	-22.42%	-9.98	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.29%	-15.38%	-45.68	3.85	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-3.94%	-8.31%	24.94	4.47	85.90%	-14.05%
NVAX	572.4M	983.7M	-12.98%	-52.88%	-1.05	0.58	-50.36%	17.16%
CRBP	395.6M	881.7K	7.90%	326.47%	-8.87	466.16	-77.61%	-5.33%
INO	233.7M	4.9M	-13.94%	-3.10%	-1.73	48.02	-54.97%	51.71%
IBIO	6.2M	2.1M	63.30%	36.92%	-0.23	2.14	-13.45%	66.37%

Zivo Bioscience, Inc. News

Latest updates

Zivo Bioscience, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4
Revenue	0%	12.00	12.00	4.00	179	353	527	321	164	888	1,611	219	244	270	709	720	292	662	623	254	424	117
Gross Profit	0.0%	4.00	4.00	3.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Costs and Expenses	-	-	-	-	-	-	1,706	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	20.6%	1,901	1,577	1,827	1,970	2,638	1,673	1,749	2,084	1,755	3,365	1,030	2,426	3,773	1,574	2,037	968	1,617	1,495	1,335	1,683	-
S&GA Expenses	17.1%	1,588	1,356	1,385	1,568	2,118	1,264	1,281	1,437	3,294	459	374	694	3,036	340	370	309	397	317	307	332	-
R&D Expenses	41.6%	312	221	442	402	519	409	468	647	447	1,295	437	1,576	467	526	948	366	559	555	774	927	-
Interest Expenses	-233.5%	-43.70	33.00	32.00	3.00	3.00	209*	19.00	24.00	37.00	24.00	24.00	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-4.6%	-1,908	-1,824	-2,070	-1,973	-2,640	-1,551	-1,845	-2,218	-1,893	-3,502	-1,166	-2,542	-4,131	-1,781	-2,540	-3,057	-3,097	-4,118	-3,573	-3,846	-
Net Income Margin	-Infinity%	-281.27*	-	-4.36*	-4.37*	-4.39*	-3.77*	-4.75*	-4.41*	-4.57*	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	63.7%	-715	-1,969	-985	-2,128	-1,447	-1,801	-2,048	-1,052	-901	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-73.6%	556	2,102	710	1,128	2,123	3,971	5,865	7,688	8,990	10,972	11,104	649	390	130	223	179	369	70.00	112	104	412
Current Assets	-78.2%	425	1,948	530	928	1,902	3,729	5,601	7,454	8,960	10,935	11,062	458	168	130	223	179	369	70.00	112	104	412
Cash Equivalents	-81.5%	274	1,485	21.00	209	1,799	3,386	5,084	6,599	8,902	10,803	10,903	232	138	55.00	119	10.00	346	15.00	44.00	4.00	389
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	-13.6%	2,762	3,196	3,855	2,870	2,134	2,447	2,854	3,104	2,948	3,201	3,771	12,073	11,531	11,221	10,216	9,327	8,708	10,973	11,271	24,803	22,694
Current Liabilities	-13.0%	2,762	3,174	3,804	2,791	2,028	2,315	2,697	2,959	2,948	3,198	3,642	11,941	11,394	11,100	10,094	9,327	8,708	10,973	11,271	24,803	22,694
Shareholder's Equity	-Infinity%	-2,205	-	-	-	-10.62	1,524	3,010	4,585	6,042	7,771	7,333	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-1.6%	-123,581	-121,673	-119,848	-117,777	-115,804	-113,163	-112,327	-110,255	-107,059	-104,712	-103,128	-101,282	-99,063	-97,170	-93,667	-92,500	-89,957	-85,826	-84,044	-81,504	-78,447
Additional Paid-In Capital	0.7%	121,373	120,577	116,694	116,027	115,792	114,679	115,328	114,830	113,092	112,474	110,452	89,438	87,748	85,673	83,268	82,949	81,223	74,565	72,544	56,619	55,986
Shares Outstanding	36.8%	2,382	1,742	1,570	1,570	1,570	1,570	1,570	1,570	1,570	1,570	-	70,187	-	-	-	-	-	-	-	-	-
Float	-	-	-	17,300	-	-	-	28,300	-	-	-	29,200	-	-	-	27,358	-	-	-	18,826	-	-

Cashflow (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	63.7%	-715	-1,969	-985	-2,128	-1,447	-1,488	-1,305	-2,861	-1,901	-1,801	-2,048	-1,052	-901	-564	-339	-783	-651	-1,326	-1,153	-576	-1,124
Share Based Compensation	-	-	-	-	-	-	-	-	571	-	-	-	975	-	-	-	-	-	-	-	-	-
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	-114.4%	-494	3,433	798	538	-139	-209	-209	559	1*	1,702	12,720	1,146	984	501	449	447	982	1,298	1,193	192	1,285

ZIVO Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
REVENUE:
Product revenue	$ 27,650	$ 0
Total Revenues	27,650	0
COST OF GOODS SOLD
Product costs	16,040	0
Total Cost of Goods Sold	16,040	0
GROSS MARGIN	11,610	0
COSTS AND EXPENSES:
General and administrative	5,897,594	6,491,704
Research and development	1,377,028	2,240,270
Total Costs and Expenses	7,274,622	8,731,974
LOSS FROM OPERATIONS	(7,263,012)	(8,731,974)
OTHER (EXPENSE):
Amortization of debt discount	439,594	0
Interest expense - related parties	(50,785)	0
Interest expense - other	(23,793)	(13,319)
Total Other Expense	514,172	13,319
NET LOSS	$ (7,777,184)	$ (8,745,293)
BASIC AND DILUTED LOSS PER SHARE	$ (4.60)	$ (5.57)
WEIGHTED AVERAGE
BASIC AND DILUTED SHARES OUTSTANDING	1,690,009	1,569,943

ZIVO Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEET - USD ($)	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash	$ 274,380	$ 1,799,263
Accounts receivable	3,735	0
Prepaid expenses	147,262	102,416
Total current assets	425,377	1,901,679
PROPERTY AND EQUIPMENT, NET	0	0
OTHER ASSETS:
Operating lease - right of use asset	98,280	189,282
Security deposit	32,058	32,058
Total other assets	130,338	221,340
TOTAL ASSETS	555,715	2,123,019
CURRENT LIABILITIES:
Accounts payable	993,090	490,670
Accounts payable - related party	172,670	0
Current portion of long-term operating lease	106,342	99,259
Convertible debentures payable	240,000	240,000
Deferred R&D obligations - participation agreements	0	525,904
Deferred R&D obligations - participation agreements related parties	0	175,427
Accrued interest	100,686	98,286
Accrued liabilities - employee bonus	1,148,770	398,176
Total current liabilities	2,761,558	2,027,722
LONG TERM LIABILITIES:
Long-term operating lease, net of current portion	0	105,919
Total long-term liabilities	0	105,919
TOTAL LIABILITIES	2,761,558	2,133,641
STOCKHOLDERS' (DEFICIT):
Common stock, $0.001 par value, 25,000,000 and 25,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 2,382,356 and 1,569,943 issued and outstanding at December 31, 2023, and December 31, 2022, respectively	2,383	1,570
Additional paid-in capital	121,373,488	115,792,338
Accumulated deficit	(123,581,714)	(115,804,530)
Total stockholders' (deficit)	(2,205,843)	(10,622)
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT)	$ 555,715	$ 2,123,019

About Zivo Bioscience, Inc.

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

CEO	Mr. John B. Payne
WEBSITE	zivobioscience.com
INDUSTRY	Biotechnology
EMPLOYEES	8

Zivo Bioscience, Inc. Frequently Asked Questions

What is the ticker symbol for Zivo Bioscience, Inc.? What does ZIVO stand for in stocks?

ZIVO is the stock ticker symbol of Zivo Bioscience, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Zivo Bioscience, Inc. (ZIVO)?

As of Mon Apr 22 2024, market cap of Zivo Bioscience, Inc. is 22.22 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ZIVO stock?

You can check ZIVO's fair value in chart for subscribers.

What is the fair value of ZIVO stock?

You can check ZIVO's fair value in chart for subscribers. The fair value of Zivo Bioscience, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Zivo Bioscience, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ZIVO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Zivo Bioscience, Inc. a good stock to buy?

The fair value guage provides a quick view whether ZIVO is over valued or under valued. Whether Zivo Bioscience, Inc. is cheap or expensive depends on the assumptions which impact Zivo Bioscience, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ZIVO.

What is Zivo Bioscience, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 22 2024, ZIVO's PE ratio (Price to Earnings) is -2.86 and Price to Sales (PS) ratio is 803.66. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ZIVO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Zivo Bioscience, Inc.'s stock?

In the past 10 years, Zivo Bioscience, Inc. has provided 0.354 (multiply by 100 for percentage) rate of return.